For the treatment of thrombocytopenia in adult patients with chronic liver disease before a scheduled procedure

DOPTELET Safety Profile Was Similar to Placebo1

Pooled Safety Data from ADAPT-1 and ADAPT-2 (N=430)1

Adverse drug reactions sorted in descending order by total patients treated with DOPTELET were: pyrexia, abdominal pain, nausea, headache, fatigue, and edema peripheral.

*Treatment-emergent adverse reactions sorted in descending order by total patients treated with DOPTELET (N=274).1

Low discontinuation rates  (<1%) due to adverse reactions1

Incidence of thrombosis (1/430): In ADAPT-1 and ADAPT-2 there was one treatment-emergent event of portal vein thrombosis1

Reference:

1.    DOPTELET [package insert]. Durham, NC: Dova Pharmaceuticals, Inc.; 2018.